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Background: Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used in veterinary medicine. Robenacoxib is a
NSAID with high selectivity for the cyclo-oxygenase-2 enzyme. In this study, the efficacy and safety of robenacoxib were
evaluated in a prospective, randomised, active- and placebo-controlled masked clinical trial in 147 cats undergoing
orthopaedic surgery. Cats were randomised into two treatment groups: Group 1, robenacoxib (2 mg/kg) administered
via subcutaneous (s.c.) injection before surgery, followed by robenacoxib tablets (1–2.4 mg/kg) administered
post-operatively for approximately 9 days (n = 101) and Group 2, meloxicam (0.3 mg/kg) administered s.c. before
surgery, followed by placebo tablets administered post-operatively for approximately 9 days (n = 46). Cats were
assessed using numerical rating scales (NRSs) by clinicians before surgery and at 3, 8, 22 and 28 hours after surgery and
at the final visit (VF on approximately Day 10), and daily by their owners from Day 1 to the VF.
Results: The primary end point was the global investigator score which was the sum of clinician NRSs for posture,
behaviour and pain on palpation/manipulation. The efficacy of the single robenacoxib injection, assessed during 3
to 22 hours, was statistically non-inferior to meloxicam, with a relative efficacy of 1.029 (95% confidence interval,
0.847–1.231). No significant differences were detected during the follow-up treatment with robenacoxib tablets for
approximately 9 days compared with placebo via clinician assessments at 28 hours and the VF, or in owner assessments
on Days 1–VF. There were no significant differences in frequencies of reported adverse events, clinical observations and
haematology or clinical chemistry variables between the groups.
Conclusions: Single s.c. injection of robenacoxib before surgery had non-inferior efficacy compared with meloxicam in
controlling post-operative pain and inflammation in cats undergoing orthopaedic surgery. Follow-up treatment with oral
robenacoxib tablets for approximately 9 days was well tolerated, but there were no differences in the efficacy scores after
Day 1 compared with the group receiving meloxicam s.c. followed by placebo control.
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Non-steroidal anti-inflammatory drugs (NSAIDs) are
commonly used to manage pain, inflammation and fever
[1]. Despite the recognised need for effective drugs of
this class in cats, there are relatively few preclinical and
clinical studies on NSAIDs in this species and fewer* Correspondence: jonathan.king@novartis.com
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reason for the limited availability of feline NSAIDs is the
low safety indices of many NSAIDs in cats [1].
Robenacoxib is a NSAID of the Coxib class which is
registered for use in cats and dogs. Owing to its avail-
ability as injection and tablet formulations with proven
efficacy and good safety, robenacoxib has an interesting
profile for use in cats. Robenacoxib is rapidly absorbed
after subcutaneous (s.c.) injection and oral administra-
tion in cats, with mean time to maximal concentrational. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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nacoxib demonstrated analgesic, anti-inflammatory and
anti-pyretic activity in cats in a kaolin-induced paw inflam-
mation model [3]. In clinical trials, non-inferior efficacy of
robenacoxib compared with ketoprofen was observed in
acute musculoskeletal disorders [4,5] and superior efficacy
against pain was reported versus meloxicam in cats under-
going surgery [6]. Superiority of robenacoxib tablets versus
placebo was also demonstrated in cats undergoing surgery
[7]. Robenacoxib has a high safety index in healthy cats:
oral dosages up to 20 mg/kg/day for 42 days were well
tolerated compared with the recommended dosage of 1–
2.4 mg/kg [8]. The good safety profile of robenacoxib may
be attributed to its combination of enzyme specificity (for
cyclo-oxygenase-2 (COX-2)), short half-life (~1.5 hour) in
blood and selective tissue distribution [8,9].
The aim of the present investigation was to evaluate
the field efficacy and safety of robenacoxib in controlling
peri-operative pain and inflammation associated with
orthopaedic surgery in cats. Robenacoxib (s.c. followed
by tablets) was compared with meloxicam (s.c. followed
by placebo tablets). Meloxicam is a preferential inhibitor




The study was a multi-centre, prospective, randomised,
masked, parallel-group design clinical trial comparing
two treatment groups. Group 1 received robenacoxib by
s.c. injection pre-operatively, followed by robenacoxib
tablets administered post-operatively. Group 2 received
pre-operative meloxicam by s.c. injection, followed by
post-operative placebo tablets. Meloxicam was selected as
the active control as meloxicam 5 mg/mL solution for in-
jection is registered for single use at a dose of 0.3 mg/kg,
administered before surgery, for the reduction of post-
operative pain after ovariohysterectomy and minor ortho-
paedic surgery in the European Union (EU), and for the
control of post-operative pain and inflammation associ-
ated with orthopaedic surgery, ovariohysterectomy and
castration in the United States (US). At the time the study
was initiated, meloxicam was not registered for post-
operative use in cats in the EU (or the US). Therefore
robenacoxib (s.c. injection followed by tablets) was com-
pared to single pre-operative meloxicam by s.c. injection
followed by administration of placebo tablets. The admin-
istration of placebo tablets to Group 2 was considered ac-
ceptable on welfare grounds because of the absence of
registered products at the time of the study and the fact
that meloxicam has a long duration of action in cats [10].
Clinicians were instructed to administer additional anal-
gesia of their choice as rescue therapy at any time, if
judged to be needed.The study was authorised by the French (Agence Natio-
nale du Médicaments Vétérinaire, authorization # EC/05/
043) and United Kingdom (UK) (Veterinary Medicines
Directorate, Animal Test Certificate Vm12501/0038) regu-
latory authorities and internal Novartis reviews based on
scientific, ethical and animal welfare guidelines.
The study was also conducted in compliance with: (a)
the EMEA/CVMP/237/01 document, Guideline for the
Conduct of Efficacy Studies for Non-Steroidal Anti-
Inflammatory Drugs; (b) the document, Procedures and
Principles of Good Clinical Practice as detailed in the
Veterinary International Conference on Harmonization
Guideline on Good Clinical Practices (GL9)—CVMP/
VICH/595/98; and (c) the Guideline on Statistical Princi-
ples for Veterinary Clinical Trials (EMEA/CVMP/816/
00). All owners gave written informed consent to include
their cats in the study.Animals
The inclusion criteria for cats were age ≥6 weeks, body
weight 2.5–12 kg, either sex, any breed, presenting for
major orthopaedic surgery under general anaesthesia.
The exclusion criteria for cats were pregnant or lactating
or females intended for breeding; with severe concomi-
tant disorders (e.g., gastrointestinal disease, kidney or
liver insufficiency); treated before study commencement
with local or systemic NSAIDs or opioids (within
24 hours, apart from butorphanol in the UK as part of
the pre-anaesthetic regimen), corticosteroids (short-act-
ing systemic or locally acting within 30 days, long-acting
within 60 days); and undergoing repeated surgeries
within a few days.Randomisation and blinding procedures
Animals were randomly assigned to the two treatment
groups in a 2:1 robenacoxib:meloxicam ratio from com-
puter-generated randomisation lists. The 2:1 ratio was
used to obtain data in more cats receiving robenacoxib
and was predicted to cause only a modest (approximately
10%) reduction in statistical efficiency compared to a 1:1
ratio. Case allocation was stratified according to the inves-
tigation centre and the anticipated duration of surgery
(<45 minutes, >45 minutes). Investigators were blinded to
the block length, which was six. The robenacoxib and
meloxicam solutions for injection have a different appear-
ance. Masking was therefore maintained by the ‘blinding
by function’ technique: a clinician was responsible for
clinical assessments, whereas a separate dispenser was
responsible for treatment prescription, administration
and compliance control. For the oral treatment, both
placebo and robenacoxib tablets had the same appear-
ance and packaging, therefore owners were blinded to
the treatment.
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Investigational drugs were a parenteral formulation of
robenacoxiba, a tablet formulation of robenacoxibb, a par-
enteral formulation of meloxicamc and placebo tabletsd.
Target and actual dosages are listed in Table 1. The s.c. in-
jections of robenacoxib and meloxicam were given be-
tween the shoulder blades, shortly before the induction of
anaesthesia. Owners were instructed to administer tablets
either with no food or with only a small quantity of food.
Cats received once daily one (body weight, 2.5–6.0 kg) or
two (body weight, >6.0-12.0 kg) tablets containing robena-
coxib or placebo for 9 days (range, 7–11 days). There was
no mandatory anaesthetic regimen, but times of anaes-
thetic induction, duration of anaesthesia and recovery
from anaesthesia were recorded.
All concomitant treatments were recorded. The use of
fluid therapy and antibiotics was permitted. Drugs likely
to affect efficacy assessments, including all classes of anal-
gesics (except those incorporated in the pre-anaesthetic
regimen) including other NSAIDs or corticosteroids were
forbidden, except as rescue therapy.
Study schedule
The study schedule is outlined in Table 2.
Efficacy evaluation criteria
Cats were assessed by a clinician while the cat was hos-
pitalised pre-surgery (visit (V)1) and post-surgery (V2 to
the final visit (VF)) (Table 2) for pain, posture and be-
haviour (Table 3). In addition, each owner assessed the
cat’s activity, appetite, behaviour and the interaction with
the owner and/or other people in their home environ-
ment daily from Day 1 to VF (Table 4).
The primary efficacy end point was the global investiga-
tor score (described as a multi-dimensional rating scale),
which was the non-weighted sum of the posture, behav-
iour and pain on palpation/manipulation numerical rating
scales (NRS) assessed by the clinician (Table 3). All other
efficacy assessments were secondary efficacy end points.
Plasma cortisol concentration
Blood samples were collected at time (T)0, T1, V5 and VF
(Table 2). Plasma cortisol concentrations were determined
using a commercial radio-immunoassay kit (IMMULITE®
2000 Cortisol kit, Siemens Healthcare Diagnostics, NY,
US) by personnel at the National Veterinary School ofTable 1 Treatment groups
Groups Number
of cats
s.c. dosage (mean ± S
Target A
Robenacoxib (s.c. + oral) 101 2.0 2
Meloxicam (s.c. + placebo oral) 46 0.3 0
s.c.: subcutaneous.
*Robenacoxib and placebo tablets were administered once daily for 9 (range, 7–11)Toulouse, France. Within-day and between-day precisions
were < 14%, and the accuracy ranged from 93% to 109%.
The limit of quantitation of the assay was 10 ng/mL.
Tolerability
The clinician examined each cat and checked for vomit-
ing and diarrhoea on the floor of the recovery cage at
V2, V3, V4 and V5 and, in addition, examined the cat at
VF. Owners were requested to report all adverse events
occurring from Day 1 to VF.
Pain and inflammation at the injection site
Local tolerance at injection sites was assessed by the dis-
penser using 4-point NRSs (range, 0–3) for which the
lower and upper descriptors were: (a) pain (0 = none,
3 = severe) at T0; (b) inflammation (0 = none, 3 = severe)
at T2; and (c) pain on palpation (0 = no reaction, 3 = ex-
treme reaction) at T2. These assessments were not
blinded.
Clinical chemistry and haematology
Blood samples for plasma clinical chemistry (into hep-
arin) and haematology (into EDTA) were taken before
anaesthetic induction and at V5 and VF. Variables in-
cluded activities of alanine aminotransferase (ALT), as-
partate aminotransferase (AST), alkaline phosphatase
(AP) and creatine kinase (CK), concentrations of albu-
min, creatinine, potassium, sodium, total protein and
urea, red blood cell count, white blood cell count, differ-
ential white cell count, platelet count, haematocrit and
haemoglobin concentration.
Palatability
The palatability of the tablets was assessed by the dis-
penser at V5 on Day 1 and by the owners from Day 2 to
the day preceding the VF using a 5-point NRS (Table 4).
Statistics
Data are presented as mean (SD). All analyses were based
on the ‘intention-to-treat’ data set, that is all randomised
animals that received at least the s.c. injection and from
which at least one measurement post-treatment was ob-
tained. Statistical tests were performed using SAS® Soft-
ware version 8.2 (SAS Online Doc, Version 8, Cary NC,
US; SAS Institute Inc, 1999).D) in mg/kg Daily oral dosage (mean ± SD) in mg/kg*
ctual Target Actual
.0 ± 0.09 1.0 – 2.4 1.58 ± 0.41
.3 ± 0.005 - -
days.
Table 2 Dosing and monitoring schedule
Day 0 Day 1 Day 2 to 9 Day 10
Time (T) Initial visit T0* T1a T1 + 3 hours
(±0.5 hours)
T1 + 8 hours
(±1 hours)
T1 + 22 hours
(±2 hours)




Description V1 V2 V3 V4 V5 VF





Extubation First oral dose Once-daily
oral dosesc
s.c.: subcutaneous; V: visit; VF: final visit.
*The s.c. first drug administration was close to the time of anaesthetic induction (T0).
aTime of extubation if the cat was intubated during anaesthesia or return of palpebral reflex if not intubated (T1).
bThe first tablet was administered by the dispenser approximately 24 hours after the s.c. administration (T2).
cTablets were administered from Day 2 to the day preceding the VF by the owner. The total duration of oral dosing was 9 days (range, 7–11 days).
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Whitney U test. Efficacy, cortisol, clinical chemistry and
haematology variables were analysed using repeated
measures analysis of covariance (RMANCOVA). Vari-
ables were transformed (log or reciprocal), if appropri-
ate, to give the best estimate of a normal distribution
which was assessed using the Shapiro-Wilk test.
The RMANCOVA model contained the model param-
eters: treatment group, baseline value, time, weight, age,
investigator/owner, duration of intubation and type of
surgery. Model parameters (except treatment group) that
gave a P value of >0.05 were successively deleted from
the model. Non-inferiority for efficacy variables was con-
cluded when the lower limit of the 95% confidence inter-
val (CI) for the ratio robenacoxib/meloxicam was higher
than 1–δ, with δ defined as 0.25 [11].
As many variables deviated significantly from a normal
distribution in the RMANCOVA analysis, groups were
in addition compared with the non-parametric Mann–
Whitney test. Change from baseline was assessed using
the Wilcoxon paired-samples test. The occurrence of
adverse events in the two treatment groups was com-
pared using the Fisher exact probability test. All statis-
tical tests were two-sided on a 5% level of significance
(α = 0.05).Table 3 Summary of numerical rating scales (lower and uppe
Variable Lower descriptor (0)
Posture of cat in recovery cagea Comfortable, relaxed
Behaviour of cat in recovery cagea Alert, positive interactio
when cage is opened
Pain elicited on manipulation of wound
or area of operationb
No reaction to even st
Overall pain controlc Excellent
*Each variable was assessed on a 4-point scale (0 to 3).
aAssessments at V1 to V5.
bAssessments at V1 to V5 and VF (final visit).
cAssessments at V2 to V5 and VF.
All four end points were secondary endpoints in the statistical analysis. The posture
provide the primary end point, the global investigator score.Results
Baseline and demographic variables
A total of 147 cats were recruited at 21 investigator sites
from different practices in France and the UK between De-
cember 2005 and August 2007. No cases were removed
from the analysis, leaving 147 cats in the analysed data set.
The number of cases per centre ranged from 1 to 22 (robe-
nacoxib 0 to 14, meloxicam plus placebo 0 to 8, P = 0.91).
There were no significant differences between the two
groups in baseline, surgery or anaesthetic variables (Table 5).
The duration of surgery was 60 minutes or less in 69% of
cases. The majority (51%) of cats underwent fracture repair.Efficacy
There were no significant differences between groups in
the number of cats which received additional analgesics as
rescue therapy (robenacoxib n = 2 (2%), meloxicam n = 2
(4%), P = 0.56) or which were withdrawn because of
judged lack of efficacy (robenacoxib n = 4 (4%), meloxicam
n = 0 (0%), P = 0.23). The rescue therapy was administered
by injection in all cases: 0.09 mg buprenorphine and 1 mg
methadone respectively in the two cats in the robenacoxib
group and 0.05 and 0.5 mg morphine respectively in the
two cases in the meloxicam group.r descriptors only) used by the investigator (clinician)*
Upper descriptor (3)
Rigid or tense
n with clinician Depressed, aggressive or non-responsive
to stimulation
rong manipulation Extreme reaction to any manipulation
Poor
, behaviour and pain on manipulation scores were summed for each animal to
Table 4 Summary of the numerical rating scales (lower and upper descriptors only) used by the owner*
Variable Lower descriptor (0) Upper descriptor (3)
Level of activity compared with normala Normal Severely impaired/depressed
Animal behavioura Normal, alert, content Depressed
Appetitea Good (normal or improved) Not eating
Interactions with owner, other humans,
other animals (sociability)a
Good (normal or improved) None, unresponsive
Palatability of tabletsb Excellent, voluntary intake from
owner’s hand or food/bowl
Reluctance to accept all
dosing procedures
*Each variable was assessed on a 4-point scale (0 to 3) except palatability (0 to 4). aAssessments from Day 1 to VF (final visit). The sum of the 4 scores was used to
derive a multi-dimensional rating assessment, the global owner score. The assessment form at VF was completed by the investigator and owner together.
bAssessment each day from Day 1 to day preceding VF; on Day 1 by the dispenser, on all other days by the owner.
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The efficacy of the injectable products was assessed by
comparing clinician assessments in the first 24 hours
(V2 to V4). Scores were numerically but not statistically
significantly lower (better) with robenacoxib for the pri-
mary end point and three of the five secondary end
points (Table 6). The global investigator scores were low
at all time points in both the groups and decreased with
time after T1 + 3 hours (Figure 1).
Non-inferiority analysis was conducted using RMAN-
COVA. However, in spite of the transformations, only the
primary efficacy end point, the global investigator score
fulfilled normal distribution assumptions (P = 0.20). Non-
inferiority of robenacoxib versus meloxicam was demon-
strated for the global investigator score, with the relative
efficacy of robenacoxib versus meloxicam being 1.029
(95% CI, 0.847–1.231). The effect of covariates was signifi-
cant for baseline, investigator and time (P <0.001), but was
non-significant for age, body weight, country, duration of
intubation, treatment, treatment × time interaction and
type of surgery.
All secondary end points deviated from a normal distri-
bution (P <0.05) in the RMANCOVA even after transfor-
mations (Table 6). For the primary and secondary clinician
end points, there were no significant differences between
groups in the non-parametric Mann–Whitney compari-
sons (Table 6).Efficacy from Day 1 to the VF after surgery
The efficacy of the robenacoxib tablets compared with
the placebo tablets was assessed from the clinicians’ as-
sessments at T2 + 4 hours (28 hours) and VF (Table 7)
plus the owners’ assessments on Day 1 to VF (Table 8).
In the RMANCOVA analyses, only the global investiga-
tor score was normally distributed after transformation
(P = 0.53). Clinician scores were numerically lower with
robenacoxib than meloxicam + placebo for the five sec-
ondary endpoints but not the primary endpoint, how-
ever differences were not significant using the non-
parametric Mann–Whitney test (Table 7).The scores were low in both the groups for all vari-
ables for the owner’s end points. In the RMANCOVA
analyses, all variables deviated markedly from a normal
distribution (P <0.001). Scores were numerically lower
with robenacoxib than meloxicam + placebo for four of
the five owners’ variables, but differences were not sig-
nificant with the non-parametric Mann–Whitney test
for any variable (Table 8). The global owner score results
are shown in Figure 2.
Plasma cortisol concentration
Cortisol concentrations (nmol/L; mean ± SD) for Group 1
(n = 60) and Group 2 (n = 29), respectively, were 106.1 ±
74.6 and 92.9 ± 61.5 at T0; 106.3 ± 79.8 and 109.8 ± 68.0 at
T1; 90.9 ± 87.6 and 87.8 ± 61.8 at V5; and 87.2 ± 73.6 and
90.6 ± 54.9 at VF. Thus, inter-animal variation in concen-
tration was high at all times in both the groups. The only
significant change from baseline was lower concentrations
at V5 in the robenacoxib group (P = 0.024). Differences
between groups were not statistically significant. Non-
inferiority was demonstrated in the RMANCOVA ana-
lysis, the relative efficacy (95% CI), calculated from the re-
ciprocal of cortisol concentrations, of robenacoxib versus
meloxicam + placebo was 1.148 (0.896–1.445).
Tolerability
The numbers of cats with reported adverse events, which
may or may not have been related to the robenacoxib,
meloxicam and placebo treatments, were 30/101 (30%) for
the robenacoxib group and 12/46 (26%) for the meloxi-
cam + placebo group (P = 0.70, Table 9).
A higher than 2% incidence of reported adverse events
was described only for diarrhoea, loose stool and emesis.
The reported frequency in the robenacoxib and meloxi-
cam + placebo groups, respectively, was 7% and 7% for
diarrhoea (P = 1.0), 9% and 9% for loose stool (P = 1.0),
and 13% and 11% for emesis (P = 0.79).
Pain and inflammation at the injection site
The dispenser assessed (unblinded) the pain during the
s.c. injection. The mean (SD) scores were 0.14 (0.43) with
Table 5 Baseline, surgery and anaesthetic variables
Variable Robenacoxib (s.c. + oral) Meloxicam s.c. + placebo oral Total P value
Total 101 46 147
Age 3.8 (4.1) 2.9 (3.1) 3.5 (3.8) 0.075
Body weight 4.0 (1.0) 3.8 (1.0) 3.9 (1.0) 0.26
Sex and neutered status
Male not neutered 22 (22%) 16 (35%) 38 (26%) 0.19
Female not neutered 12 (12%) 8 (17%) 20 (14%)
Male neutered 38 (38%) 15 (33%) 53 (36%)
Female neutered 29 (29%) 7 (15%) 36 (24%)
Breed
Burmese 1 (1%) 0 (0%) 1 (1%) 0.37
Crossbred 3 (3%) 0 (0%) 3 (2%)
Domestic long hair 5 (5%) 0 (0%) 5 (3%)
Domestic short hair 33 (33%) 15 (33%) 48 (33%)
European 57 (56%) 29 (63%) 86 (59%)
Persian 1 (1%) 0 (0%) 1 (1%)
Siamese 1 (1%) 2 (4%) 3 (2%)
Baseline clinician scores
Global investigator score 3.1 (1.9) 3.5 (2.3) 3.2 (2.0) 0.50
Pain at palpation/manipulation 1.5 (0.8) 1.6 (0.8) 1.5 (0.8) 0.44
Expected duration of surgery (hours)
<60 min 71 (70%) 30 (65%) 101 (69%) 0.57
>60 min 30 (30%) 16 (35%) 46 (31%)
Effective duration of surgery (hours) 53.0 (38.8) 57.9 (39.2) 54.6 (38.8) 0.41
Effective duration of intubation 80.4 (48.5) 79.5 (50.0) 80.2 (48.8) 0.82
Type of surgery
Fracture, internal repair 49 (49%) 26 (57%) 75 (51%) 0.38
Fracture, no internal repair 1 (1%) 0 (0%) 1 (1%) 1.0
Hip surgery 10 (10%) 4 (9%) 14 (10%) 1.0
Amputation, limb 6 (6%) 0 (0%) 6 (4%) 0.18
Amputation, tail or phalanx 6 (6%) 4 (9%) 10 (7%) 0.73
Joint surgery 13 (13%) 6 (13%) 19 (13%) 1.0
Removal of osteosynthesis material 13 (13%) 3 (7%) 16 (11%) 0.28
Miscellaneous 2 (2%) 2 (4%) 4 (3%) 0.59
Combinations 1 (1%) 1 (2%) 2 (1%) 1.0
Substances used in anaesthesia
Acepromazine 22 (22%) 12 (26%) 34 (23%) 0.67
Butorphanol 33 (33%) 15 (33%) 48 (33%) 1.0
Diazepam 6 (6%) 4 (9%) 10 (7%) 0.73
Ketamine 57 (56%) 28 (61%) 85 (58%) 0.72
Medetomidine 54 (53%) 17 (37%) 71 (48%) 0.076
Medetomidine/acepromazine 0 (0%) 1 (2%) 1 (1%) 0.31
Propofol 33 (33%) 12 (26%) 45 (31%) 0.450
Thiopental 5 (5%) 3 (7%) 8 (5%) 1.0
Tiletamine/zolazepam 7 (7%) 2 (4%) 9 (6%) 0.72
Xylazine 18 (18%) 11 (24%) 29 (20%) 0.50
s.c.: subcutaneous.
Data are mean (SD) or number of cats (%).
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Transformation for RMANCOVA analysis
Mean (SD) Mean (SD) Mean 95% CI Transformation P value for normality
(Shapiro-Wilks test)
Global investigator score (primary
end point)
V2-V4 2.72 (1.42) 2.80 (1.62) 0.76 1.029 0.847–1.231 0.76 0 (log) 0.20
Posture V2-V4 0.68 (0.53) 0.79 (0.61) 0.38 1.144 0.821–1.538 0.39 −1 (reciprocal) <0.0001
Behaviour V2-V4 0.81 (0.56) 0.88 (0.64) 0.91 1.073 0.827–1.360 0.58 −0.5 (reciprocal of
square root)
0.024
Pain on palpation/manipulation V2-V4 1.22 (0.69) 1.14 (0.69) 0.23 0.979 0.799–1.184 0.82 0.5 (square root) 0.0024
Overall pain control V2-V4 1.17 (0.76) 1.15 (0.67) 0.89 1.120 0.880–1.408 0.34 0.5 (square root) 0.011
Sedation V2-V4 0.44 (0.44) 0.40 (0.42) 0.76 0.945 0.396–1.755 0.85 −0.5 (reciprocal of
square root)
0.024
CI: confidence interval; s.c.: subcutaneous.
Values are mean (SD) for each group and quotient values with 95% CIs for the ratio robenacoxib/meloxicam. Data are from the assessments at V2, V3 and V4. Non-inferiority of robenacoxib versus meloxicam was
concluded if the lower limit of the 95% CI was >0.75 (shown in bold). P values <0.05 are also shown in bold.
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Figure 1 Mean (±SD) global investigator scores at assessment
times V1 to V5. For an explanation of the global investigator scores
(0 = best possible, 9 = worst possible) see Table 3.
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were not significant (P = 0.87). At T2 (approximately
24 hours after the s.c. injection), the dispenser assessed in-
flammation and pain at palpation at the original site of in-
jection. The mean (SD) scores for robenacoxib and
meloxicam were, respectively, 0.05 (0.22) and 0.05 (0.21)
for inflammation (P = 1.0), and 0.03 (0.17) and 0.05 (0.21)
for pain on palpation (P = 1.0) (data not shown).Clinical chemistry
At V5 (28 hours post-surgery), the following changes
from baseline were significant: in both the groups, AST,
CK and potassium were increased, whereas AP and albu-
min were decreased; in the robenacoxib group, creatinine
was decreased; and in the meloxicam group, urea was in-
creased and total protein was decreased. At VF in both the
groups, ALT, AST and CK were significantly decreased
compared with baseline and AP, creatinine, sodium and
urea were significantly increased. Differences between
groups were significant for creatinine and urea with higher
values in the meloxicam + placebo group (data not shown).Haematology
At V5 (28 hours post-surgery), red and white cell counts,
haemoglobin and haematocrit were significantly increased
compared with baseline in the robenacoxib group. At VF,
red cell counts, haemoglobin and haematocrit were sig-
nificantly increased compared with baseline in the robena-
coxib group. The only significant change from baseline in
the meloxicam + placebo group was a decrease in white
cell counts at the VF. The only significant difference be-
tween the two treatment groups was lower white cell
counts in the meloxicam group (data not shown).Palatability
The palatability of the tablets containing robenacoxib
was compared with placebo by the dispenser at V5 on
Day 1 and by the owners daily from Day 2 to the VF.
Differences between groups were not significant. The
mean (SD) scores in the robenacoxib and placebo groups
were, respectively, 1.46 (1.03) and 1.28 (0.88) for the dis-
penser (P = 0.38) and 1.15 (1.09) and 1.16 (0.88) for the
owner (P = 0.54).
Discussion
The principal finding of this study is that single s.c. in-
jection of robenacoxib before surgery was well tolerated
and had statistically non-inferior efficacy in comparison
with meloxicam for the management of pain and inflam-
mation associated with orthopaedic surgery in cats. Both
drugs provided good efficacy, as evidenced from low
scores for pain and inflammation post-surgery and low
frequency of rescue therapy.
The primary end point, the global investigator score,
was the unweighted sum of three secondary end points
(behaviour, posture and pain on palpation). This end
point fulfilled normal distribution assumptions after log
transformation, permitting non-inferiority of the robena-
coxib injection versus meloxicam to be tested (and dem-
onstrated) using the powerful parametric RMANCOVA
analysis. The relative efficacy (95% CI) of robenacoxib
versus meloxicam was 1.029 (0.847-1.231), showing nu-
merical but not significantly superior efficacy of robena-
coxib. All five secondary investigator end points showed
significant deviation from a normal distribution even
after transformation, therefore statistical comparison be-
tween groups for these end points had to be based on
lack of significant differences using the non-parametric
Mann–Whitney test.
Meloxicam injection was selected as the positive control
as it is registered and extensively used, and its efficacy is
documented in the literature in cats. The superiority of
meloxicam by injection at the 0.3 mg/kg dose versus
placebo was demonstrated in experimental models of
endotoxin-induced fever (intravenous administration) [12]
and kaolin-induced fever, pain and inflammation (s.c. ad-
ministration) [10]. The superiority of meloxicam injection
in cats undergoing ovariohysterectomy was also reported
versus placebo and buprenorphine [13,14]. In addition,
equivalent efficacy of meloxicam has been reported in cats
compared with butorphanol for onychectomy [15], and
compared with carprofen, ketoprofen and tolfenamic acid
[16], carprofen [17] and tolfenamic acid [13] for ovario-
hysterectomy. Therefore, there is sufficient evidence pub-
lished for the efficacy of meloxicam to control pain and
inflammation in cats undergoing orthopaedic surgery to
justify its use as a positive control for this study. However,
in none of the mentioned published studies were the same











Transformation for RMANCOVA analysis
Mean (SD) Mean (SD) Mean 95% CI Exponential P value for normality
(Shapiro-Wilks test)
Global investigator score (primary
end point)
V5 1.86 (1.61) 1.98 (1.91) 0.93 0.968 0.682–1.316 0.84 0 (log) 0.53
Posture V5 0.70 (0.68) 0.78 (0.74) 0.72 1.007 0.527–1.693 0.98 −1 (reciprocal) <0.0001
Behaviour V5 0.42 (0.59) 0.54 (0.84) 1.0 1.064 0.565–1.786 0.82 −0.5 (reciprocal of square
root)
<0.0001
Pain on palpation/manipulation V5 &
VF
0.44 (0.62) 0.52 (0.84) 0.65 1.032 0.768–1.343 0.82 0.5 (square root) <0.0001
Overall pain control V5 &
VF
0.76 (0.62) 0.76 (0.71) 0.49 1.143 0.807–1.567 0.42 0.5 (square root) <0.0001
Inflammation intensity VF 0.15 (0.04) 0.25 (0.06) 0.16 1.642 0.752–3.695 0.18 0 (log) <0.0001
CI: confidence interval; s.c.: subcutaneous; VF: final visit.
Values are mean (SD) for each group and quotient values with 95% CI for the ratio robenacoxib/meloxicam. Data are from assessments at V5 and VF.
Non-inferiority of robenacoxib versus meloxicam was concluded if the lower limit of the 95% CI was >0.75 (shown in bold). P values <0.05 are also shown in bold.





















P value (RMANCOVA) Transformation for RMANCOVA
analysis
Mean (SD) Mean (SD) Mean 95% CI Exponential P value for normality
(Shapiro-Wilks test)
Level of activity D1-VF 0.62 (0.53) 0.64 (0.61) 0.96 0.972 0.658–1.373 0.87 0 (log) <0.0001
Behaviour D1-VF 0.29 (0.38) 0.31 (0.34) 0.57 1.285 0.731–2.240 0.34 −1 (reciprocal) <0.0001
Appetite D1-VF 0.38 (0.48) 0.37 (0.49) 0.69 1.006 0.551–1.672 0.98 −1 (reciprocal) <0.0001
Interaction D1-VF 0.23 (0.34) 0.26 (0.33) 0.70 1.306 0.696–2.452 0.36 −1 (reciprocal) <0.0001
Global owner score D1-VF 1.52 (1.42) 1.58 (1.45) 0.87 1.050 0.719–1.482 0.78 0 (log) <0.0001
CI: confidence interval; VF: final visit.
Values are mean (SD) for each group and quotient values with 95% CI for the ratio robenacoxib/meloxicam. All assessments made by the owners are secondary end points. Assessments were made daily from the day
after surgery (Day 1) to VF.
Non-inferiority of robenacoxib versus meloxicam was concluded if the lower limit of the 95% CI was >0.75 (shown in bold). P values <0.05 are also shown in bold.












Time (D = day)


















Robenacoxib s.c. + oral 
Meloxicam s.c. + oral placebo
Figure 2 Mean (±SD) global owner scores from Day 1 to the
VF. For an explanation of the global owner score (0 = best possible,
12 = worst possible) see Table 4.
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signed non-inferiority studies, the methods and outcome
measures should be similar to those used in the original
studies of the active control [18].
Although the primary objective of the study was the









0/101 (0%) 1/46 (2%) 0.31
Anorexia 1/101 (1%) 0/46 (0%) 1.0
Blood in faeces 1/101 (1%) 1/46 (2%) 1.0
Diarrhoea 7/101 (7%) 3/46 (7%) 1.0
Disorientation 1/101 (1%) 0/46 (0%) 1.0
Emesis 13/101 (13%) 5/46 (11%) 0.79
Eye redness 1/101 (1%) 0/46 (0%) 1.0
Loose stool 9/101 (9%) 4/46 (9%) 1.0
Muscle tremor 1/101 (1%) 0/46 (0%) 1.0
Pain not otherwise
specified
0/101 (0%) 1/46 (2%) 0.31
Polydipsia 0/101 (0%) 1/46 (2%) 0.31
Prostration 1/101 (1%) 0/46 (0%) 1.0
Prolonged recovery 1/101 (1%) 0/46 (0%) 1.0
Sneezing 1/101 (1%) 0/46 (0%) 1.0
Spasm 0/101 (0%) 1/46 (2%) 0.31
Vocalisation 0/101 (0%) 1/46 (2%) 0.31
Uncoded sign 2/101 (2%) 1/46 (2%) 1.0
Any adverse event 30/101 (30%) 12/46 (26%) 0.70
s.c.: subcutaneous.
Data are number of cats with reported adverse event/total number of cats (%)
in the whole study.versus meloxicam injection, the effects of follow-up treat-
ment with robenacoxib tablets for approximately 9 days
were assessed as a secondary objective. During the follow-
ing examinations by the clinician at V5 (28 hours post-
surgery) and VF, non-inferior efficacy of robenacoxib
versus the control group was demonstrated for pain on
palpation and overall pain control. Non-inferiority was
also shown for inflammation intensity which was assessed
at VF. Comparison of robenacoxib tablets versus placebo
tablets from Day 1 to VF showed low scores on all days
with no significant differences between groups. This result
may reflect the possibility that a single pre-surgical admin-
istration of robenacoxib or meloxicam was sufficient to
control post-operative pain and inflammation in most
cats. However, it is also recognised that the methods for
assessment of efficacy after Day 1 were not optimal; the
veterinarians made only assessments at V5 and VF, and
the owner evaluations assessed animal demeanour and
general well-being (level of activity, behaviour, appetite,
and interaction) and did not monitor anti-hyperalgesic ac-
tions. The benefit of administration of robenacoxib tablets
for 2 days after surgery in cats was demonstrated statisti-
cally versus placebo in another study [7].
Anaesthesia and surgery are both potential stressors.
Therefore plasma cortisol, a stressor glucocorticoid bio-
marker, was measured at four pre-determined times
to compare the effects of the two NSAIDs. In both the
groups, mean values remained relatively constant at the
first three sampling times (T0, T1 and V5) and then
increased moderately but significantly at VF. Differ-
ences between groups were not statistically significant.
Lower plasma cortisol concentrations post-surgery were
reported previously in cats receiving meloxicam com-
pared with butorphanol [15], vedaprofen compared with
placebo [19] and fentanyl compared to control [20]. How-
ever, the relevance of plasma cortisol is not clear, as no
differences in plasma cortisol concentrations between sur-
gery and control cats were reported in another study [21].
There were no significant differences in the frequency
of reported adverse events in the two groups (P = 0.070).
Several clinical chemistry and haematology variables in-
creased compared with baseline in both the groups, and
these changes were attributed to the anaesthetic proto-
cols and surgical procedures rather than the NSAIDs.
The only significant differences between the two groups
were higher values for plasma creatinine and urea in the
meloxicam group. These results may be type I errors, as
the frequency is consistent with the multiple analyses (17
variables at two time points) and an alpha value of 5%.
The rationale for the development of highly COX-2 se-
lective NSAIDs, such as robenacoxib, is that they should
offer the same efficacy but better safety than older less se-
lective NSAIDs, such as meloxicam [3]. The finding of no
significant differences in tolerability between robenacoxib
Speranza et al. BMC Veterinary Research  (2015) 11:79 Page 12 of 13and meloxicam + placebo in this study is not surprising
however, as the study was underpowered to detect differ-
ences in safety parameters, with only 147 cats and a rela-
tively short treatment duration (maximum 12 days). In
addition, we did not include specific safety investigations,
for example gastroscopy, which might have revealed dif-
ferences in tolerability.
The major limitations of the study are discussed here.
First, the scoring schemes used have not been validated
in cats. Second, the frequency of assessments was rela-
tively sparse, especially the follow-up from Day 2 on-
wards, and consisted of daily assessments of the cat’s
demeanour and general well-being by the owner. Third,
with the exception of the primary end point (the global
investigator score), statistical comparisons of efficacy data
had to rely on non-parametric statistics because of lack of
normal distribution of the data. Reliable non-inferiority
analyses could only be performed using RMANCOVA for
the primary end point. Fourth, the limitations of non-
inferiority studies using positive controls are well known
[18]. In our study the proven non-inferiority of robena-
coxib versus meloxixam could be due to the fact that both
NSAIDs were similarly effective or ineffective, or alter-
natively that the study lacked sensitivity. It was judged that
the use of a placebo pre-surgery would have been une-
thical, as a number of NSAIDs are registered for pre-
operative use in cats in the EU and are widely used. In
addition, as noted previously, the efficacy of both meloxi-
cam [10,12] and robenacoxib [3,7] in cats versus placebo
has been shown previously A feature of our study was the
choice of a non-inferiority threshold (δ) value of 0.25. The
δ value should reflect the largest margin that is clinically
acceptable, but to date no specific guidelines on δ values
for veterinary NSAIDs have been published. In fact, the
results show that non-inferior efficacy of robenacoxib to
the positive control would also have been achieved if we
had defined δ = 0.16 for the primary end point, that is with
a maximum of 16% difference in the global investigator
score. Furthermore, robenacoxib had numerical superior-
ity to meloxicam for the primary end point (relative effi-
cacy 1.029), which supports the conclusion of non-inferior
efficacy.
Conclusions
Single s.c. injection of robenacoxib (2 mg/kg) before sur-
gery had good tolerability and non-inferior efficacy com-
pared with meloxicam (0.3 mg/kg) for the control of pain
and inflammation in cats undergoing orthopaedic surgery.
Follow-up treatment with oral robenacoxib tablets for ap-
proximately 9 days was well tolerated, but there were no
differences in the efficacy scores after Day 1 compared with
the group receiving meloxicam s.c. followed by placebo
control. This might be the result of single pre-surgical ad-
ministration of robenacoxib leading to adequate control ofpain and inflammation in most cats. However, it is also
recognised that the methods for assessment of efficacy
after Day 1 were not optimal.
Endnotes
aOnsior® solution for injection 2%, Novartis Animal
Health Inc, Basel, Switzerland.
bOnsior® non-divisible tablets containing 6 mg of robe-
nacoxib, Novartis Animal Health Inc, Basel, Switzerland.
cMetacam® 5 mg/mL injectable, Boehringer Ingelheim
Inc, Ingelheim, Germany.
dPlacebo tablets manufactured by Novartis Animal
Health Inc, Basel, Switzerland with identical appearance
to the Onsior® tablets
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